Thomas Stock

Efficacy and Safety of CE-224,535, an Antagonist of P2X₇Receptor, in Treatment of Patients with Rheumatoid Arthritis Inadequately Controlled by Methotrexate

Thomas Stock, Bradley J. Bloom, Nathan Wei et al. · The Journal of Rheumatology · 2012 · 238 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Model-Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development

Peter A. Milligan, Marcy Brown, B Marchant et al. · Clinical Pharmacology & Therapeutics · 2013 · 236 citations

Medicine, Pharmacology, Clinical Pharmacology +10

Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study

Nicolino Ruperto, Hermine I. Brunner, Zbigniew Żuber et al. · Pediatric Rheumatology · 2017 · 97 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Extended‐Release Once‐Daily Formulation of Tofacitinib: Evaluation of Pharmacokinetics Compared With Immediate‐Release Tofacitinib and Impact of Food

Manisha Lamba, Rong Wang, Tracey Fletcher et al. · The Journal of Clinical Pharmacology · 2016 · 76 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +16

Maraviroc, a chemokine receptor-5 antagonist, fails to demonstrate efficacy in the treatment of patients with rheumatoid arthritis in a randomized, double-blind placebo-controlled trial

Dona Fleishaker, Juan A. García Meijide, Michael Kohen et al. · Arthritis Research & Therapy · 2012 · 68 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +14